Risk factor
High price volatility
Profitability factor
Very favourable analyst view
About
Zylox-Tonbridge Medical Technology Co., Ltd. is a global medical device firm specializing in neurovascular and peripheral vascular interventional technologies. Their comprehensive product line for treating ischemic stroke includes the ThromBite Clot Retriever, designed to extract clots from major brain vessels, as well as aspiration and balloon guiding catheters. For peripheral vascular conditions, they offer the ZENFLEX Pro Drug-eluting Stent System for managing complex and recurring symptomatic lesions, the self-expanding ZENFlex Peripheral Stent System for deployment in the iliac, superficial femoral, and proximal popliteal arteries, and drug-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters for treating arterial stenoses or blockages in these same regions. Their neurovascular offerings further extend to Ton-Bridge extra soft coils, utilized for the endovascular embolization of intracranial aneurysms and other cerebral vascular malformations like arteriovenous malformations (AVMs) and fistulae. Supporting these are a range of microcatheters (for coiling or selective agent delivery), distal access and intracranial PTA balloon catheters, vascular snares, and IVC filter snare retrieval kits. Established in 2012, Zylox-Tonbridge Medical Technology Co., Ltd. maintains its headquarters in Zhejiang, People's Republic of China.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, 'expensi
Target Price
The average target price of 2190.HK is 29.9 and suggests 52.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i